Navigation Links
OncoGenex Pharmaceuticals CEO Named Canada's Pacific Ernst & Young's Entrepreneur Of The Year(R) in the Health Sciences Category
Date:10/9/2009

of people who inspire others with their vision, leadership and achievement. The Ernst & Young Entrepreneur Of The Year(R) award celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 135 cities in 50 countries. Award winners were selected by an independent judging panel made up of regional business, academic and community leaders.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

More information about OncoGenex is available at www.oncogenex.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning Fast Track Designation for OGX-011 and anticipated clinical and other product development activities and timing of these activities. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. All stat
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 /PRNewswire/ ... has announced the addition of Jain PharmaBiotech,s ... Companies" to their offering. ... the pharmaceutical and biotechnology industries is anticipated. ... of drug development - from formulations for ...
(Date:9/2/2015)... 2015 Research and ... of Jain PharmaBiotech,s new report "Biochips and ... their offering. This report is an ... applications. The report starts with a description of ... Technologies include array comparative genomic hybridization (CGH), copy ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... announced the addition of Jain PharmaBiotech,s new report ... their offering. The markets for gene therapy ... approved gene therapy product and it is marketed in ... markets are estimated for the years 2014-2024. The estimates ...
(Date:9/2/2015)... Mass. (PRWEB) , ... September 02, 2015 , ... ... includes development of botanical and plant-derived compounds. BCC Research reveals in its ... past 2020 because this market defines the category and generates the most market ...
Breaking Biology Technology:Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3
... (OTC Bulletin Board: MLSS), the recognized leader in advanced,injection ... Annual,Meeting of Stockholders on Thursday, June 5, 2008 beginning ... Brown, Rudnick, Berlack and Israels,located at 7 Times Square ... of the close of business on April 25, 2008,will ...
... Inc.,(Nasdaq: ORCH ), a leading worldwide provider ... in its sales and marketing organization., Jeffrey ... of North,America Marketing and Sales. Based in Orchid ... will oversee sales and,marketing for Orchid,s North America ...
... Results Fail to Show Statistically Significant Improvement in Primary ... Endpoint, Time to Progression, Compared to Control, ... announced results from the Company,s Phase 3 registration trial,of ... (NHL)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080404/LAF521LOGO ), Analysis ...
Cached Biology Technology:Milestone Scientific to Host 2008 Annual Meeting of Stockholders on Thursday, June 5, 2008 in New York City 2Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales 2Orchid Cellmark Appoints Jeffrey S. Boschwitz as Vice President, North America Marketing & Sales 3Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 2Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma 3
(Date:8/12/2015)... 2015  New research unveiled at Black Hat ... to steal users, fingerprints. Information released today by ... scanners on mobile devices, making the security of ... on mobile devices, HYPR Corp. recently released a ... systems with strong cryptographic security. More information on ...
(Date:8/10/2015)... LONDON , August 10, 2015 ... visiongain offers comprehensive analysis of the global border ... will generate revenues of $16.4bn in 2015. Now: ... This is an example of the business critical issue you ... to read visiongain ,s objective analysis of how this ...
(Date:8/5/2015)... 2015 According to a new ... Software, Services, Vertical (BFSI, Airport, IT & Telecom, Utilities, ... Forecast to 2020", published by MarketsandMarkets, defines and segments ... various segments. The global PIAM Market is estimated to ... by 2019, at a CAGR of 14.9 % from ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... are aware of the importance of nutrition and physical ... diet and engage in exercise, according to the American ... Trends 2008. In each ADA survey since ... of different questions to segment consumers into three groups ...
... CAMBRIDGE, Mass., Nov. 6, 2008 -- Billions of tons of ... into the atmosphere in the coming decades as a result ... interplay between peat bogs, water tables, and climate change. ... the carbon locked away in the world,s peat bogs would ...
... Cambridge, UK ,Discussion of a man,s background, attitude, and ... City episodes in the future, it could also be ... Risk of developing type 2 diabetes and metabolic syndrome is ... has in turn been influenced by environment and behavior, it,s ...
Cached Biology News:American Dietetic Association releases 2008 nutrition trends survey 2Global warming predicted to hasten carbon release from peat bogs 2Coping and copulation behavior may help calculate diabetes risk 2
...
Standard Fluka For microscopy (Bact., Hist.)...
Request Info...
... CLS number is a new product ... product number. If showing no availability ... Sigma-Aldrich number (Z71,405-4) or contact customer ... 60 mm volume diam. 3 ...
Biology Products: